CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PLx Opco Winddown Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PLx Opco Winddown Corp.
9 Fishers Lane
Suite E
Phone: (713) 842-1249p:713 842-1249 Sparta, NJ  07871  United States

Filed for Bankruptcy on 4/13/2023
Case #23-10457, filed in the U.S. Bankruptcy Court for the District of Delaware
This entity represents the bankrupt estate of the former businesses (assets) of PLx Pharma Winddown Corp. and PLx Opco Winddown Corp. that were not sold to PLx Acquisition Company, LLC on 5/26/2023.
This is a Subsidiary, click here for the Parent Company

Business Summary
PLx Opco Winddown Corp., formerly known as PLX Opco Inc., formerly PLx Pharma Inc., is a pharmaceutical company. The Company focuses on developing the PLxGuard delivery system to provide oral drugs for cardiovascular disease. The Company's PLxGuard delivery system works by releasing active pharmaceutical ingredients into the duodenum, the first part of the small intestine immediately below the stomach, rather than in the stomach itself. The Company's product candidates include PL2200 Aspirin, 325 mg; PL2200 Aspirin, 81 mg; PL1200 Ibuprofen, 200 mg; PL1100 Ibuprofen, 400 mg; PL5100 diclofenac, 50 mg, and PL4100 Indomethacin. The PL2200 Aspirin, 325 mg and PL2200 Aspirin, 81 mg products are used for cardiovascular disease prevention and rheumatologic. PL1200 Ibuprofen, 200 mg is used for over-the-counter pain, inflammation and fever. PL1100 Ibuprofen, 400 mg is used for pain, inflammation, osteoarthritis and rheumatologic arthritis. Its PL5100 diclofenac, 50 mg, and PL4100 Indomethacin are in clinical trials.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201512/31/2014YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Michael J.Valentino
President, Chief Executive Officer, Board Member Ronald R.Zimmerman
Chief Operating Officer, Board Member Gary L.Mossman 70
Senior Vice President Upendra K.Marathi
Vice President Jason E.Moore

Business Names
Business Name
PLX Chile SpA
PLXP

General Information
Outstanding Shares: 9,365,823 (As of 9/30/2015)
Stock Exchange: NASD
Federal Tax Id: 383976588


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023